Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2016018537
pages 569-589

Advanced Implantable Drug Delivery Systems via Continuous Manufacturing

Mohammed Maniruzzaman
Pharmaceutics Research Lab, School of Life Sciences, University of Sussex, Sussex, UK
Ali Nokhodchi
Pharmaceutics Research Lab, School of Life Sciences, University of Sussex, Sussex, UK; Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

ABSTRAKT

Polymeric implantable drug delivery systems have remarkable potential for systemic delivery of various therapeutic agents. Generally, drug-loaded implants do not require a vehicle for delivery and can be used to attain prolonged delivery into the systemic circulation of active pharmaceutical ingredients (APIs) with enhanced drug bioavailability. Furthermore, implants can provide drug release ranging from months to years, which improves patient compliance, especially for poorly bioavailable and rapidly metabolized compounds. Continuous manufacturing technology (e.g., hot-melt extrusion, or HME) has been successfully employed to prepare drug-loaded single-unit polymeric implants. Employing heat and mechanical shear, such systems retain the stability of thermolabile therapeutics (e.g., proteins) in implants. HME has emerged as important because of its varied applications that combine economic viability with solvent-free and easy scale-up processing. Moreover, it has been recognized from a quality-by-design (QbD) viewpoint by the FDA.


Articles with similar content:

Review Article: Fabricated Microparticles: An Innovative Method to Minimize the Side Effects of NSAIDs in Arthritis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 5
Shaivad Shabee Hulhasan Abadi, Afrasim Moin, Gangadharappa Hosahalli Veerabhadrappa
Recent Developments in the Use of Bioadhesive Systems for Delivery of Drugs to the Oral Cavity
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.21, 2004, issue 4
John D. Smart
Polyphosphates and Other Phosphorus-Containing Polymers for Drug Delivery Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 4
Stephanie T. Lopina, Duane F. Bruley, Mahesh V. Chaubal, Anirban Sen Gupta
Immunoisolation Cell Therapy for CNS Diseases
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.18, 2001, issue 3
Shelly R. Winn, Dwaine F. Emerich
Biopolymers as Transdermal Drug Delivery Systems in Dermatology Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 2
M.A. Navya, K. H. Basavaraj, Siddaramaiah, George Johnsy, R. Rashmi